30/06/2009

Amarillo, CytoPharm intiates enrollment for hepatitis-C study

Aim of trial is to reduce virologic relapse rate for patients who have completed the standard combination therapy.

Amarillo (ABI) and CytoPharm have started the enrollment for a study of ABI's oral interferon-alpha lozenges, for chronic hepatitis-C virus infection.

The aim of the trial is to reduce the virologic relapse rate for patients who have completed the standard combination therapy, which consists of high dose injectable interferon-alpha and Ribavirin. Although most patients respond to the standard therapy, up to 50% of those with certain high-risk viral genotypes relapse after treatment.

In this study, a total of 165 patients who test positive for a high-risk hepatitis C viral genotype, will receive one of two different doses of human interferon-alpha or placebo given daily for 24 weeks. Full study enrollment is expected to complete by the end of the year.

The companies announced that CytoPharm is planning a study of oral interferon lozenges in the treatment of influenza, which is to be launched during the 2009/2010 flu season in Taiwan.

Pharmaceutical Business Review

http://www.pharmaceutical-business-review.com/

http://www.pharmaceutical-business-review.com/news/amarillo_cytopharm_intiates_enrollment_for_hepatitisc_study_090629

Share this page

More...

DISCLAIMER

The EATG is not responsible for the content of this article. It does not necessarily reflect EATG views or opinions.

FAIR USE NOTICE

The information above may contain copyrighted material which has not always been specifically authorised by the copyright owner. Such material is made available for educational purposes to advance the understanding of scientific, ethical, legal and social issues. It is believed that this constitutes a 'fair use' of any such copyrighted material. This material is distributed without profit via the subscription to the daily digest.